CS223818B2 - Means for afinity for the jeundice virus - Google Patents
Means for afinity for the jeundice virus Download PDFInfo
- Publication number
- CS223818B2 CS223818B2 CS764537A CS453776A CS223818B2 CS 223818 B2 CS223818 B2 CS 223818B2 CS 764537 A CS764537 A CS 764537A CS 453776 A CS453776 A CS 453776A CS 223818 B2 CS223818 B2 CS 223818B2
- Authority
- CS
- Czechoslovakia
- Prior art keywords
- water
- conjugate
- agarose
- composition
- permeable matrix
- Prior art date
Links
- 241000700605 Viruses Species 0.000 title claims abstract description 22
- 239000000203 mixture Substances 0.000 claims abstract description 46
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims abstract description 41
- 239000011159 matrix material Substances 0.000 claims abstract description 23
- 208000006454 hepatitis Diseases 0.000 claims abstract description 18
- 231100000283 hepatitis Toxicity 0.000 claims abstract description 18
- 230000002209 hydrophobic effect Effects 0.000 claims abstract description 7
- 125000004432 carbon atom Chemical group C* 0.000 claims abstract 2
- 125000006850 spacer group Chemical group 0.000 claims description 20
- 239000002253 acid Substances 0.000 claims description 13
- 229920000936 Agarose Polymers 0.000 claims description 7
- QTBSBXVTEAMEQO-UHFFFAOYSA-N acetic acid Substances CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 claims description 6
- 229920002401 polyacrylamide Polymers 0.000 claims description 6
- SXRSQZLOMIGNAQ-UHFFFAOYSA-N Glutaraldehyde Chemical compound O=CCCCC=O SXRSQZLOMIGNAQ-UHFFFAOYSA-N 0.000 claims description 5
- 150000001875 compounds Chemical class 0.000 claims description 5
- BRLQWZUYTZBJKN-UHFFFAOYSA-N Epichlorohydrin Chemical compound ClCC1CO1 BRLQWZUYTZBJKN-UHFFFAOYSA-N 0.000 claims description 4
- AFOSIXZFDONLBT-UHFFFAOYSA-N divinyl sulfone Chemical compound C=CS(=O)(=O)C=C AFOSIXZFDONLBT-UHFFFAOYSA-N 0.000 claims description 4
- QWVCIORZLNBIIC-UHFFFAOYSA-N 2,3-dibromopropan-1-ol Chemical compound OCC(Br)CBr QWVCIORZLNBIIC-UHFFFAOYSA-N 0.000 claims description 3
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical group [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 claims description 3
- 239000004952 Polyamide Substances 0.000 claims description 3
- 150000001720 carbohydrates Chemical class 0.000 claims description 3
- 239000001913 cellulose Substances 0.000 claims description 3
- 229920002678 cellulose Polymers 0.000 claims description 3
- 229920003023 plastic Polymers 0.000 claims description 3
- 239000004033 plastic Substances 0.000 claims description 3
- 229920002647 polyamide Polymers 0.000 claims description 3
- 229960002703 undecylenic acid Drugs 0.000 claims description 2
- MQANMCFSNPBYCQ-UHFFFAOYSA-N decan-2-amine Chemical compound CCCCCCCCC(C)N MQANMCFSNPBYCQ-UHFFFAOYSA-N 0.000 claims 1
- KDYFGRWQOYBRFD-UHFFFAOYSA-M succinate(1-) Chemical compound OC(=O)CCC([O-])=O KDYFGRWQOYBRFD-UHFFFAOYSA-M 0.000 claims 1
- 210000002381 plasma Anatomy 0.000 abstract description 41
- 238000000034 method Methods 0.000 abstract description 20
- 239000012620 biological material Substances 0.000 abstract description 5
- 239000003446 ligand Substances 0.000 abstract description 4
- 239000000427 antigen Substances 0.000 description 63
- 238000012360 testing method Methods 0.000 description 36
- RYHBNJHYFVUHQT-UHFFFAOYSA-N 1,4-Dioxane Chemical compound C1COCCO1 RYHBNJHYFVUHQT-UHFFFAOYSA-N 0.000 description 34
- 239000000243 solution Substances 0.000 description 25
- 239000000872 buffer Substances 0.000 description 22
- 238000001179 sorption measurement Methods 0.000 description 18
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 16
- NAQMVNRVTILPCV-UHFFFAOYSA-N hexane-1,6-diamine Chemical compound NCCCCCCN NAQMVNRVTILPCV-UHFFFAOYSA-N 0.000 description 16
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 15
- 229920002684 Sepharose Polymers 0.000 description 14
- 238000003556 assay Methods 0.000 description 13
- 238000004519 manufacturing process Methods 0.000 description 11
- 238000006243 chemical reaction Methods 0.000 description 10
- 239000006228 supernatant Substances 0.000 description 10
- FPOGSOBFOIGXPR-UHFFFAOYSA-N 2-octylbutanedioic acid Chemical compound CCCCCCCCC(C(O)=O)CC(O)=O FPOGSOBFOIGXPR-UHFFFAOYSA-N 0.000 description 9
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 9
- 239000000047 product Substances 0.000 description 9
- 238000003756 stirring Methods 0.000 description 9
- 239000011780 sodium chloride Substances 0.000 description 8
- 239000007858 starting material Substances 0.000 description 8
- 239000011521 glass Substances 0.000 description 7
- 239000000463 material Substances 0.000 description 7
- YLAXZGYLWOGCBF-UHFFFAOYSA-N 2-dodecylbutanedioic acid Chemical compound CCCCCCCCCCCCC(C(O)=O)CC(O)=O YLAXZGYLWOGCBF-UHFFFAOYSA-N 0.000 description 6
- ZMXDDKWLCZADIW-UHFFFAOYSA-N N,N-Dimethylformamide Chemical compound CN(C)C=O ZMXDDKWLCZADIW-UHFFFAOYSA-N 0.000 description 6
- 210000004369 blood Anatomy 0.000 description 6
- 239000008280 blood Substances 0.000 description 6
- 239000012131 assay buffer Substances 0.000 description 5
- MHZGKXUYDGKKIU-UHFFFAOYSA-N Decylamine Chemical compound CCCCCCCCCCN MHZGKXUYDGKKIU-UHFFFAOYSA-N 0.000 description 4
- QOSSAOTZNIDXMA-UHFFFAOYSA-N Dicylcohexylcarbodiimide Chemical compound C1CCCCC1N=C=NC1CCCCC1 QOSSAOTZNIDXMA-UHFFFAOYSA-N 0.000 description 4
- 206010023126 Jaundice Diseases 0.000 description 4
- 238000002360 preparation method Methods 0.000 description 4
- KDYFGRWQOYBRFD-UHFFFAOYSA-L succinate(2-) Chemical compound [O-]C(=O)CCC([O-])=O KDYFGRWQOYBRFD-UHFFFAOYSA-L 0.000 description 4
- 239000000725 suspension Substances 0.000 description 4
- PRPINYUDVPFIRX-UHFFFAOYSA-N 1-naphthaleneacetic acid Chemical compound C1=CC=C2C(CC(=O)O)=CC=CC2=C1 PRPINYUDVPFIRX-UHFFFAOYSA-N 0.000 description 3
- -1 4- glycylnorleucine Chemical compound 0.000 description 3
- BVKZGUZCCUSVTD-UHFFFAOYSA-L Carbonate Chemical compound [O-]C([O-])=O BVKZGUZCCUSVTD-UHFFFAOYSA-L 0.000 description 3
- PIICEJLVQHRZGT-UHFFFAOYSA-N Ethylenediamine Chemical compound NCCN PIICEJLVQHRZGT-UHFFFAOYSA-N 0.000 description 3
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 3
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 3
- 102000013566 Plasminogen Human genes 0.000 description 3
- 108010051456 Plasminogen Proteins 0.000 description 3
- ZMANZCXQSJIPKH-UHFFFAOYSA-N Triethylamine Chemical compound CCN(CC)CC ZMANZCXQSJIPKH-UHFFFAOYSA-N 0.000 description 3
- 102000036639 antigens Human genes 0.000 description 3
- 108091007433 antigens Proteins 0.000 description 3
- 239000003795 chemical substances by application Substances 0.000 description 3
- 229960001231 choline Drugs 0.000 description 3
- 239000012141 concentrate Substances 0.000 description 3
- ATDGTVJJHBUTRL-UHFFFAOYSA-N cyanogen bromide Chemical compound BrC#N ATDGTVJJHBUTRL-UHFFFAOYSA-N 0.000 description 3
- 229940099500 cystamine Drugs 0.000 description 3
- 238000005194 fractionation Methods 0.000 description 3
- 239000000523 sample Substances 0.000 description 3
- 239000012279 sodium borohydride Substances 0.000 description 3
- 229910000033 sodium borohydride Inorganic materials 0.000 description 3
- HZAXFHJVJLSVMW-UHFFFAOYSA-N 2-Aminoethan-1-ol Chemical compound NCCO HZAXFHJVJLSVMW-UHFFFAOYSA-N 0.000 description 2
- FPQQSJJWHUJYPU-UHFFFAOYSA-N 3-(dimethylamino)propyliminomethylidene-ethylazanium;chloride Chemical compound Cl.CCN=C=NCCCN(C)C FPQQSJJWHUJYPU-UHFFFAOYSA-N 0.000 description 2
- 102000009027 Albumins Human genes 0.000 description 2
- 108010088751 Albumins Proteins 0.000 description 2
- 102000015081 Blood Coagulation Factors Human genes 0.000 description 2
- 108010039209 Blood Coagulation Factors Proteins 0.000 description 2
- UIIMBOGNXHQVGW-UHFFFAOYSA-M Sodium bicarbonate Chemical compound [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 description 2
- 230000004913 activation Effects 0.000 description 2
- 125000001931 aliphatic group Chemical group 0.000 description 2
- WPYMKLBDIGXBTP-UHFFFAOYSA-N benzoic acid Chemical compound OC(=O)C1=CC=CC=C1 WPYMKLBDIGXBTP-UHFFFAOYSA-N 0.000 description 2
- 239000003114 blood coagulation factor Substances 0.000 description 2
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 description 2
- 238000001514 detection method Methods 0.000 description 2
- 239000012153 distilled water Substances 0.000 description 2
- 229960000587 glutaral Drugs 0.000 description 2
- MNWFXJYAOYHMED-UHFFFAOYSA-N heptanoic acid Chemical compound CCCCCCC(O)=O MNWFXJYAOYHMED-UHFFFAOYSA-N 0.000 description 2
- 230000001900 immune effect Effects 0.000 description 2
- 230000002163 immunogen Effects 0.000 description 2
- XNGIFLGASWRNHJ-UHFFFAOYSA-N phthalic acid Chemical compound OC(=O)C1=CC=CC=C1C(O)=O XNGIFLGASWRNHJ-UHFFFAOYSA-N 0.000 description 2
- KIDHWZJUCRJVML-UHFFFAOYSA-N putrescine Chemical compound NCCCCN KIDHWZJUCRJVML-UHFFFAOYSA-N 0.000 description 2
- 238000003127 radioimmunoassay Methods 0.000 description 2
- 230000035945 sensitivity Effects 0.000 description 2
- 210000002966 serum Anatomy 0.000 description 2
- CDBYLPFSWZWCQE-UHFFFAOYSA-L sodium carbonate Substances [Na+].[Na+].[O-]C([O-])=O CDBYLPFSWZWCQE-UHFFFAOYSA-L 0.000 description 2
- NWZSZGALRFJKBT-KNIFDHDWSA-N (2s)-2,6-diaminohexanoic acid;(2s)-2-hydroxybutanedioic acid Chemical compound OC(=O)[C@@H](O)CC(O)=O.NCCCC[C@H](N)C(O)=O NWZSZGALRFJKBT-KNIFDHDWSA-N 0.000 description 1
- RNHDAKUGFHSZEV-UHFFFAOYSA-N 1,4-dioxane;hydrate Chemical compound O.C1COCCO1 RNHDAKUGFHSZEV-UHFFFAOYSA-N 0.000 description 1
- BMVXCPBXGZKUPN-UHFFFAOYSA-N 1-hexanamine Chemical compound CCCCCCN BMVXCPBXGZKUPN-UHFFFAOYSA-N 0.000 description 1
- FRPZMMHWLSIFAZ-UHFFFAOYSA-N 10-undecenoic acid Chemical compound OC(=O)CCCCCCCCC=C FRPZMMHWLSIFAZ-UHFFFAOYSA-N 0.000 description 1
- RVHOBHMAPRVOLO-UHFFFAOYSA-N 2-ethylbutanedioic acid Chemical compound CCC(C(O)=O)CC(O)=O RVHOBHMAPRVOLO-UHFFFAOYSA-N 0.000 description 1
- OAJCSERLBQROJC-UHFFFAOYSA-N 3-octyloxolane-2,5-dione Chemical compound CCCCCCCCC1CC(=O)OC1=O OAJCSERLBQROJC-UHFFFAOYSA-N 0.000 description 1
- 244000105624 Arachis hypogaea Species 0.000 description 1
- 239000005711 Benzoic acid Substances 0.000 description 1
- 241000283707 Capra Species 0.000 description 1
- 241000700721 Hepatitis B virus Species 0.000 description 1
- AVXURJPOCDRRFD-UHFFFAOYSA-N Hydroxylamine Chemical compound ON AVXURJPOCDRRFD-UHFFFAOYSA-N 0.000 description 1
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
- 102000006835 Lamins Human genes 0.000 description 1
- 108010047294 Lamins Proteins 0.000 description 1
- 239000005700 Putrescine Substances 0.000 description 1
- PLZVEHJLHYMBBY-UHFFFAOYSA-N Tetradecylamine Chemical compound CCCCCCCCCCCCCCN PLZVEHJLHYMBBY-UHFFFAOYSA-N 0.000 description 1
- 239000007983 Tris buffer Substances 0.000 description 1
- 239000003463 adsorbent Substances 0.000 description 1
- 239000012670 alkaline solution Substances 0.000 description 1
- 125000000217 alkyl group Chemical group 0.000 description 1
- 150000001412 amines Chemical class 0.000 description 1
- 239000007900 aqueous suspension Substances 0.000 description 1
- 235000010233 benzoic acid Nutrition 0.000 description 1
- 239000012503 blood component Substances 0.000 description 1
- KHAVLLBUVKBTBG-UHFFFAOYSA-N caproleic acid Natural products OC(=O)CCCCCCCC=C KHAVLLBUVKBTBG-UHFFFAOYSA-N 0.000 description 1
- 150000001718 carbodiimides Chemical class 0.000 description 1
- 238000009903 catalytic hydrogenation reaction Methods 0.000 description 1
- 210000004027 cell Anatomy 0.000 description 1
- 238000005119 centrifugation Methods 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- 235000012000 cholesterol Nutrition 0.000 description 1
- OEYIOHPDSNJKLS-UHFFFAOYSA-N choline Chemical compound C[N+](C)(C)CCO OEYIOHPDSNJKLS-UHFFFAOYSA-N 0.000 description 1
- 239000000306 component Substances 0.000 description 1
- 239000012468 concentrated sample Substances 0.000 description 1
- 238000001816 cooling Methods 0.000 description 1
- VXVVUHQULXCUPF-UHFFFAOYSA-N cycloheptanamine Chemical compound NC1CCCCCC1 VXVVUHQULXCUPF-UHFFFAOYSA-N 0.000 description 1
- OOTFVKOQINZBBF-UHFFFAOYSA-N cystamine Chemical compound CCSSCCN OOTFVKOQINZBBF-UHFFFAOYSA-N 0.000 description 1
- 238000000502 dialysis Methods 0.000 description 1
- 230000004069 differentiation Effects 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 238000004090 dissolution Methods 0.000 description 1
- 230000000311 effect on hepatitis Effects 0.000 description 1
- 150000002148 esters Chemical class 0.000 description 1
- 125000004494 ethyl ester group Chemical group 0.000 description 1
- DNJIEGIFACGWOD-UHFFFAOYSA-N ethyl mercaptane Natural products CCS DNJIEGIFACGWOD-UHFFFAOYSA-N 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 210000003608 fece Anatomy 0.000 description 1
- 238000001914 filtration Methods 0.000 description 1
- 239000012847 fine chemical Substances 0.000 description 1
- JEGUKCSWCFPDGT-UHFFFAOYSA-N h2o hydrate Chemical compound O.O JEGUKCSWCFPDGT-UHFFFAOYSA-N 0.000 description 1
- 230000035931 haemagglutination Effects 0.000 description 1
- 208000002672 hepatitis B Diseases 0.000 description 1
- IKDUDTNKRLTJSI-UHFFFAOYSA-N hydrazine monohydrate Substances O.NN IKDUDTNKRLTJSI-UHFFFAOYSA-N 0.000 description 1
- 239000005457 ice water Substances 0.000 description 1
- 238000003018 immunoassay Methods 0.000 description 1
- 230000000951 immunodiffusion Effects 0.000 description 1
- 238000000760 immunoelectrophoresis Methods 0.000 description 1
- 230000002427 irreversible effect Effects 0.000 description 1
- 238000002955 isolation Methods 0.000 description 1
- 210000005053 lamin Anatomy 0.000 description 1
- 230000003902 lesion Effects 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 229910052751 metal Inorganic materials 0.000 description 1
- 239000002184 metal Substances 0.000 description 1
- 150000002739 metals Chemical class 0.000 description 1
- 150000002923 oximes Chemical class 0.000 description 1
- 239000002245 particle Substances 0.000 description 1
- 238000009832 plasma treatment Methods 0.000 description 1
- QQONPFPTGQHPMA-UHFFFAOYSA-N propylene Natural products CC=C QQONPFPTGQHPMA-UHFFFAOYSA-N 0.000 description 1
- 125000004805 propylene group Chemical group [H]C([H])([H])C([H])([*:1])C([H])([H])[*:2] 0.000 description 1
- 238000002731 protein assay Methods 0.000 description 1
- 102000004169 proteins and genes Human genes 0.000 description 1
- 108090000623 proteins and genes Proteins 0.000 description 1
- 239000011541 reaction mixture Substances 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 230000004044 response Effects 0.000 description 1
- 229920006395 saturated elastomer Polymers 0.000 description 1
- 239000002002 slurry Substances 0.000 description 1
- 229910052708 sodium Inorganic materials 0.000 description 1
- 239000011734 sodium Substances 0.000 description 1
- 229910000030 sodium bicarbonate Inorganic materials 0.000 description 1
- 235000017557 sodium bicarbonate Nutrition 0.000 description 1
- 229910000029 sodium carbonate Inorganic materials 0.000 description 1
- 239000001509 sodium citrate Substances 0.000 description 1
- NLJMYIDDQXHKNR-UHFFFAOYSA-K sodium citrate Chemical compound O.O.[Na+].[Na+].[Na+].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O NLJMYIDDQXHKNR-UHFFFAOYSA-K 0.000 description 1
- 239000012064 sodium phosphate buffer Substances 0.000 description 1
- 239000002689 soil Substances 0.000 description 1
- 239000002904 solvent Substances 0.000 description 1
- 230000007480 spreading Effects 0.000 description 1
- 238000003892 spreading Methods 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 239000001384 succinic acid Substances 0.000 description 1
- 238000000967 suction filtration Methods 0.000 description 1
- 238000010189 synthetic method Methods 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 210000002700 urine Anatomy 0.000 description 1
- 238000003828 vacuum filtration Methods 0.000 description 1
- 238000005406 washing Methods 0.000 description 1
- 239000002351 wastewater Substances 0.000 description 1
- DGVVWUTYPXICAM-UHFFFAOYSA-N β‐Mercaptoethanol Chemical compound OCCS DGVVWUTYPXICAM-UHFFFAOYSA-N 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
- A61K35/14—Blood; Artificial blood
- A61K35/16—Blood plasma; Blood serum
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L2/00—Methods or apparatus for disinfecting or sterilising materials or objects other than foodstuffs or contact lenses; Accessories therefor
- A61L2/0005—Methods or apparatus for disinfecting or sterilising materials or objects other than foodstuffs or contact lenses; Accessories therefor for pharmaceuticals, biologicals or living parts
- A61L2/0082—Methods or apparatus for disinfecting or sterilising materials or objects other than foodstuffs or contact lenses; Accessories therefor for pharmaceuticals, biologicals or living parts using chemical substances
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L2/00—Methods or apparatus for disinfecting or sterilising materials or objects other than foodstuffs or contact lenses; Accessories therefor
- A61L2/02—Methods or apparatus for disinfecting or sterilising materials or objects other than foodstuffs or contact lenses; Accessories therefor using physical phenomena
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L2/00—Methods or apparatus for disinfecting or sterilising materials or objects other than foodstuffs or contact lenses; Accessories therefor
- A61L2/16—Methods or apparatus for disinfecting or sterilising materials or objects other than foodstuffs or contact lenses; Accessories therefor using chemical substances
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/576—Immunoassay; Biospecific binding assay; Materials therefor for hepatitis
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2730/00—Reverse transcribing DNA viruses
- C12N2730/00011—Details
- C12N2730/10011—Hepadnaviridae
- C12N2730/10111—Orthohepadnavirus, e.g. hepatitis B virus
- C12N2730/10151—Methods of production or purification of viral material
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
- Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10S436/00—Chemistry: analytical and immunological testing
- Y10S436/82—Hepatitis associated antigens and antibodies
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
- Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10S436/00—Chemistry: analytical and immunological testing
- Y10S436/825—Pretreatment for removal of interfering factors from sample
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
- Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10S530/00—Chemistry: natural resins or derivatives; peptides or proteins; lignins or reaction products thereof
- Y10S530/806—Antigenic peptides or proteins
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
- Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10S530/00—Chemistry: natural resins or derivatives; peptides or proteins; lignins or reaction products thereof
- Y10S530/82—Proteins from microorganisms
- Y10S530/826—Viruses
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
- Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10S530/00—Chemistry: natural resins or derivatives; peptides or proteins; lignins or reaction products thereof
- Y10S530/827—Proteins from mammals or birds
- Y10S530/829—Blood
- Y10S530/83—Plasma; serum
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- General Health & Medical Sciences (AREA)
- Immunology (AREA)
- Biomedical Technology (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Hematology (AREA)
- Epidemiology (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Zoology (AREA)
- Cell Biology (AREA)
- Molecular Biology (AREA)
- Biotechnology (AREA)
- Organic Chemistry (AREA)
- Virology (AREA)
- Wood Science & Technology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Biochemistry (AREA)
- Genetics & Genomics (AREA)
- Microbiology (AREA)
- Urology & Nephrology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pharmacology & Pharmacy (AREA)
- Developmental Biology & Embryology (AREA)
- Physics & Mathematics (AREA)
- General Physics & Mathematics (AREA)
- Pathology (AREA)
- Food Science & Technology (AREA)
- Communicable Diseases (AREA)
- Analytical Chemistry (AREA)
- General Engineering & Computer Science (AREA)
- General Chemical & Material Sciences (AREA)
- Peptides Or Proteins (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
SE7507854A SE417613B (sv) | 1975-07-09 | 1975-07-09 | Forfarande for separation eller koncentrering av hepatitvirus ur blandningar av biologiskt material |
SE7605632A SE421076B (sv) | 1976-05-18 | 1976-05-18 | Forfarande for separation eller koncentrering av hepatitvirus ur blandningar av biologiskt material |
Publications (1)
Publication Number | Publication Date |
---|---|
CS223818B2 true CS223818B2 (en) | 1983-11-25 |
Family
ID=26656635
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CS764537A CS223818B2 (en) | 1975-07-09 | 1976-07-08 | Means for afinity for the jeundice virus |
Country Status (20)
Country | Link |
---|---|
US (1) | US4168300A (pl) |
JP (1) | JPS5210416A (pl) |
AT (1) | AT355215B (pl) |
AU (1) | AU510068B2 (pl) |
CA (1) | CA1076956A (pl) |
CH (1) | CH630115A5 (pl) |
CS (1) | CS223818B2 (pl) |
DE (1) | DE2630753A1 (pl) |
DK (1) | DK148874C (pl) |
ES (1) | ES449670A1 (pl) |
FI (1) | FI55868C (pl) |
FR (1) | FR2317309A1 (pl) |
GB (1) | GB1531558A (pl) |
IE (1) | IE43952B1 (pl) |
IL (1) | IL49752A (pl) |
IT (1) | IT1062511B (pl) |
NL (1) | NL7607647A (pl) |
NO (1) | NO148339C (pl) |
NZ (1) | NZ181384A (pl) |
PL (1) | PL105363B1 (pl) |
Families Citing this family (38)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
SE420977B (sv) * | 1976-03-18 | 1981-11-16 | Kabi Ab | Forfarande for rening och isolering av hepatitvirus for vaccinframstellning |
SE452336B (sv) * | 1978-06-16 | 1987-11-23 | Boehringer Mannheim Gmbh | Forfarande for pavisning av sjukdomsalstrande mikroorganismer vilka adsorberats extrakorporalt pa en selektivt bindande adsorbent |
US4282315A (en) * | 1979-09-13 | 1981-08-04 | Corning Glass Works | Preparation of enriched whole virus radioligand |
US4282287A (en) * | 1980-01-24 | 1981-08-04 | Giese Roger W | Biochemical avidin-biotin multiple-layer system |
US4478914B1 (en) * | 1980-01-24 | 1997-06-17 | Roger W Giese | Process for applying multiple layers of a protein and a ligand extender to a surface and to the multiple layer system |
USRE31712E (en) * | 1980-01-24 | 1984-10-23 | Biochemical avidin-biotin multiple-layer system | |
US4440679A (en) * | 1980-03-05 | 1984-04-03 | Cutter Laboratories, Inc. | Pasteurized therapeutically active protein compositions |
US4411795A (en) * | 1980-03-10 | 1983-10-25 | Baxter Travenol Laboratories, Inc. | Particle adsorption |
US4381239A (en) * | 1981-02-10 | 1983-04-26 | Tanabe Seiyaku Co., Ltd. | Method for reducing the pyrogen content of or removing pyrogens from substances contaminated therewith |
US4511473A (en) * | 1982-02-09 | 1985-04-16 | Amf Incorporated | Fibrous media containing millimicron-sized particulates |
US4488969A (en) * | 1982-02-09 | 1984-12-18 | Amf Incorporated | Fibrous media containing millimicron-sized particulates |
US4596660A (en) * | 1982-07-23 | 1986-06-24 | Amf Inc. | Fibrous media containing millimicron-sized particulates |
US4434093A (en) | 1982-07-26 | 1984-02-28 | Ortho Diagnostic Systems Inc. | Methods for preparation of HBs Ag free gamma globulins |
JPS5961887U (ja) * | 1982-10-15 | 1984-04-23 | 三菱化学株式会社 | コ−クス自動選別装置 |
US4515714A (en) * | 1983-03-09 | 1985-05-07 | Juridicial Foundation, The Chemo-Semo-Sero-Therapeutic Research Institute | Method for purification of hepatitis B virus surface antigen |
US4627915A (en) * | 1983-04-06 | 1986-12-09 | Asahi Kasei Kogyo Kabushiki Kaisha | Absorbent of autoantibody and immune complexes, adsorbing device and blood purifying apparatus comprising the same |
WO1984004696A1 (en) * | 1983-05-31 | 1984-12-06 | Baxter Travenol Lab | Particle adsorption |
US4764369A (en) * | 1983-07-14 | 1988-08-16 | New York Blood Center Inc. | Undenatured virus-free biologically active protein derivatives |
US4820805A (en) * | 1983-07-14 | 1989-04-11 | New York Blood Center, Inc. | Undenatured virus-free trialkyl phosphate treated biologically active protein derivatives |
CA1237998A (en) * | 1984-04-14 | 1988-06-14 | Akihiro Ginnaga | Method for purification of filamentous hemagglutinin |
JPS6147186A (ja) * | 1984-08-09 | 1986-03-07 | Chemo Sero Therapeut Res Inst | インフルエンザウイルスの精製方法 |
JPS6147185A (ja) * | 1984-08-09 | 1986-03-07 | Chemo Sero Therapeut Res Inst | 日本脳炎ウイルスの精製方法 |
JPS6147187A (ja) * | 1984-08-10 | 1986-03-07 | Chemo Sero Therapeut Res Inst | 狂犬病ウイルスの精製方法 |
JPS61103895A (ja) * | 1984-10-26 | 1986-05-22 | Green Cross Corp:The | HBsAgの精製方法 |
CA1244349A (en) * | 1985-06-26 | 1988-11-08 | Jen-Chang Hsia | Purification of hemoglobin and modified hemoglobin by affinity chromatography |
CA1306190C (en) * | 1987-01-21 | 1992-08-11 | Robin M. Pennington | Immunoassay utilizing microparticle neutralization |
US4869826A (en) * | 1987-09-01 | 1989-09-26 | Process Biotechnology, Inc. | Cellular adsorbents for removal of viral contaminants from blood and complex protein solutions |
JP2729484B2 (ja) * | 1988-04-28 | 1998-03-18 | 株式会社ミドリ十字 | アンチトロンビン−▲iii▼の精製方法 |
JP2852307B2 (ja) * | 1989-02-09 | 1999-02-03 | 吉富製薬株式会社 | ウイルスの除去された蛋白質製剤の製造法 |
US5274081A (en) * | 1989-09-20 | 1993-12-28 | Immuno A.G. | Complex suitable for carrying out a method of purifying pre-S hepatitis B surface antigen |
US5576175A (en) * | 1989-09-20 | 1996-11-19 | Immuno Aktiengesellschaft | Complex suitable for carrying out a method of purifying pre-S hepatitis B surface antigen |
US5076933A (en) * | 1990-06-29 | 1991-12-31 | Coulter Corporation | Process and apparatus for removal of dna and viruses |
US5221483A (en) * | 1990-06-29 | 1993-06-22 | Coulter Corporation | Process and apparatus for removal of DNA, viruses and endotoxins |
EP1386660B1 (en) * | 1996-08-30 | 2009-09-02 | Upfront Chromatography A/S | Isolation of immunoglobulins |
WO2009132330A2 (en) * | 2008-04-25 | 2009-10-29 | Biotrove, Inc. | Separation cartridges and methods for fabrication and use thereof |
CN106138851A (zh) * | 2016-09-08 | 2016-11-23 | 四川聚豪生物科技有限公司 | 一种可有效治疗乙肝的汤剂药物及其制备方法 |
CN109867737B (zh) * | 2019-02-27 | 2022-03-18 | 宁波大学 | 一种双子型酰肼阴离子引发剂及其制备与使用方法 |
CN109896976B (zh) * | 2019-02-27 | 2022-07-12 | 宁波大学 | 一种十六代酰肼羧酸钠引发剂及其制备与使用方法 |
Family Cites Families (14)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US3425962A (en) * | 1966-12-28 | 1969-02-04 | Bristol Myers Co | Salt of a diethylaminoethyl cross-linked dextran anion exchanger |
US3636191A (en) * | 1969-10-08 | 1972-01-18 | Cancer Res Inst | Vaccine against viral hepatitis and process |
GB1392181A (en) * | 1971-04-16 | 1975-04-30 | Rech Et Dapplications Soc Gen | Fixation of nitrogenous materials |
US3852157A (en) * | 1971-05-14 | 1974-12-03 | Syva Corp | Compounds for enzyme amplification assay |
SE361320B (pl) * | 1972-03-14 | 1973-10-29 | Exploaterings Ab Tbf | |
JPS5533442B2 (pl) * | 1972-09-14 | 1980-08-30 | ||
ZA74350B (en) * | 1973-01-30 | 1974-11-27 | Baxter Laboratories Inc | Fractionation of blood |
SE413986B (sv) * | 1973-03-23 | 1980-07-07 | Exploaterings Ab Tbf | Sett att separera amfipatiska emnen innehallande bade hydrofila och hydrofoba grupper samt gelprodukt for genomforande av separationen |
US3951937A (en) * | 1973-12-20 | 1976-04-20 | The Community Blood Council Of Greater New York, Inc. | Large scale purification of hepatitis type B antigen using polyethylene glycol |
US3994870A (en) * | 1974-01-31 | 1976-11-30 | The Community Blood Council Of Greater New York, Inc. | Purification of hepatitis B surface antigen |
CS171963B1 (pl) * | 1974-02-01 | 1976-11-29 | ||
US4000098A (en) * | 1974-08-16 | 1976-12-28 | Palo Alto Medical Research Foundation | Separation of proteins by hydrophobic adsorption |
US3992517A (en) * | 1975-02-19 | 1976-11-16 | Pfizer Inc. | Detection of hepatitis B surface antigen by latex agglutination |
US3976767A (en) * | 1975-04-14 | 1976-08-24 | The New York Blood Center | Purification of hepatitis B surface antigen by chromatography on agarose containing aminoalkyl residues |
-
1976
- 1976-06-09 IL IL49752A patent/IL49752A/xx unknown
- 1976-07-01 IE IE1442/76A patent/IE43952B1/en unknown
- 1976-07-02 CA CA256,207A patent/CA1076956A/en not_active Expired
- 1976-07-05 NZ NZ181384A patent/NZ181384A/xx unknown
- 1976-07-05 IT IT25026/76A patent/IT1062511B/it active
- 1976-07-06 CH CH864976A patent/CH630115A5/de not_active IP Right Cessation
- 1976-07-06 US US05/702,666 patent/US4168300A/en not_active Expired - Lifetime
- 1976-07-07 AU AU15684/76A patent/AU510068B2/en not_active Expired
- 1976-07-08 DK DK308476A patent/DK148874C/da active
- 1976-07-08 FI FI761997A patent/FI55868C/fi not_active IP Right Cessation
- 1976-07-08 DE DE19762630753 patent/DE2630753A1/de active Granted
- 1976-07-08 GB GB28533/76A patent/GB1531558A/en not_active Expired
- 1976-07-08 CS CS764537A patent/CS223818B2/cs unknown
- 1976-07-08 NO NO762392A patent/NO148339C/no unknown
- 1976-07-08 ES ES449670A patent/ES449670A1/es not_active Expired
- 1976-07-08 AT AT500576A patent/AT355215B/de not_active IP Right Cessation
- 1976-07-08 PL PL1976191019A patent/PL105363B1/pl unknown
- 1976-07-09 FR FR7621173A patent/FR2317309A1/fr active Granted
- 1976-07-09 JP JP51081880A patent/JPS5210416A/ja active Granted
- 1976-07-09 NL NL7607647A patent/NL7607647A/xx not_active Application Discontinuation
Also Published As
Publication number | Publication date |
---|---|
PL191019A1 (pl) | 1978-04-24 |
FI761997A (pl) | 1977-01-10 |
IT1062511B (it) | 1984-10-20 |
DK148874C (da) | 1986-04-14 |
US4168300A (en) | 1979-09-18 |
NZ181384A (en) | 1978-12-18 |
IL49752A (en) | 1979-07-25 |
NO148339C (no) | 1983-09-21 |
IE43952L (en) | 1977-01-09 |
FI55868B (fi) | 1979-06-29 |
IE43952B1 (en) | 1981-07-15 |
FR2317309A1 (fr) | 1977-02-04 |
AU1568476A (en) | 1978-01-12 |
FI55868C (fi) | 1979-10-10 |
AT355215B (de) | 1980-02-25 |
PL105363B1 (pl) | 1979-10-31 |
CA1076956A (en) | 1980-05-06 |
DK148874B (da) | 1985-11-04 |
GB1531558A (en) | 1978-11-08 |
AU510068B2 (en) | 1980-06-05 |
DE2630753A1 (de) | 1977-01-20 |
ATA500576A (de) | 1979-07-15 |
NO762392L (pl) | 1977-01-11 |
DK308476A (da) | 1977-01-10 |
JPS641444B2 (pl) | 1989-01-11 |
NO148339B (no) | 1983-06-13 |
JPS5210416A (en) | 1977-01-26 |
ES449670A1 (es) | 1978-02-01 |
FR2317309B1 (pl) | 1979-06-01 |
DE2630753C2 (pl) | 1989-01-19 |
NL7607647A (nl) | 1977-01-11 |
IL49752A0 (en) | 1976-08-31 |
CH630115A5 (de) | 1982-05-28 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CS223818B2 (en) | Means for afinity for the jeundice virus | |
Truffa-Bachi et al. | Specific separation of cells on affinity columns | |
US4433059A (en) | Double antibody conjugate | |
Thouvenot et al. | Radioimmunoassay for zearalenone and zearalanol in human serum: production, properties, and use of porcine antibodies | |
US4469797A (en) | Digoxigenin immunogens, antibodies, labeled conjugates, and related derivatives | |
US4882423A (en) | Substance-conjugated complement component C1q | |
EP0196787B2 (en) | Process for detection of aflatoxins | |
JPH0779694B2 (ja) | 蛋白質および同類品の保護 | |
WO1983000505A1 (en) | Assay for viruses | |
EP0491362B1 (de) | Verwendung von Peptidpaaren mit extrem hoher spezifischer Affinität zueinander im Bereich der in vitro Diagnostik | |
US5035995A (en) | Test method involving substance-conjugated complement component C1q | |
Lenkei et al. | Methods for detection of anti-albumin autoantibodies in hepatic diseases | |
JP4182269B2 (ja) | 生体分子のポリサッカライド接合体 | |
EP0662480A1 (en) | Purification of hapten-carrier generated antibodies | |
EP0177023A2 (en) | Substance-conjugated complement component C1q | |
Lundgren et al. | Intracellular antigen of sea urchin eggs and embryos studied on ultrathin sections | |
AU553361B2 (en) | Assay for viruses | |
Ishikawa et al. | Antibody Production in Human Tonsil—Detection of Antibody Forming Cell, and Antigen Binding Cell to Dermatophagoides Farinae | |
DE2421789C3 (de) | Biologisch aktive Produkte und Verfahren zu ihrer Herstellung | |
SU1638163A1 (ru) | Способ получени конъюгата авидина с коллоидным золотом | |
RU2065164C1 (ru) | Диагностическая тест-система для выявления вируса гепатита а | |
BE843598A (fr) | Compositions ayant une affinité pour le virus d'hépatite et procéd´d'élimination de l'hépatite | |
JPS62258399A (ja) | C−反応性蛋白質の精製方法 | |
JPH01227961A (ja) | アンジオテンシン2の酵素免疫化学的測定方法 | |
CH630410A5 (en) | Process for preparing a biological substance which is bound to a poly(hydroxymethylene) support matrix |